MX360330B - Regimen de administracion para nitrocatecoles. - Google Patents

Regimen de administracion para nitrocatecoles.

Info

Publication number
MX360330B
MX360330B MX2015018058A MX2015018058A MX360330B MX 360330 B MX360330 B MX 360330B MX 2015018058 A MX2015018058 A MX 2015018058A MX 2015018058 A MX2015018058 A MX 2015018058A MX 360330 B MX360330 B MX 360330B
Authority
MX
Mexico
Prior art keywords
nitrocatechols
administration regime
regime
administration
substituents
Prior art date
Application number
MX2015018058A
Other languages
English (en)
Inventor
Alexander Learmonth David
Manuel Vieira Araújo Soares Da Silva Patricio
Luis DE ALMEIDA José
Original Assignee
Bial Portela & Ca Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bial Portela & Ca Sa filed Critical Bial Portela & Ca Sa
Publication of MX360330B publication Critical patent/MX360330B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)

Abstract

La presente invención se relaciona con regímenes de dosificación novedosos para compuestos de fórmula I (ver Fórmula) donde los sustituyentes son como se define en la especificación.
MX2015018058A 2008-07-29 2009-07-29 Regimen de administracion para nitrocatecoles. MX360330B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13724808P 2008-07-29 2008-07-29
PCT/PT2009/000044 WO2010014025A1 (en) 2008-07-29 2009-07-29 Administration regime for nitrocatechols

Publications (1)

Publication Number Publication Date
MX360330B true MX360330B (es) 2018-10-30

Family

ID=41130570

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2011001046A MX2011001046A (es) 2008-07-29 2009-07-29 Regimen de administracion para nitrocatecoles.
MX2015018058A MX360330B (es) 2008-07-29 2009-07-29 Regimen de administracion para nitrocatecoles.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2011001046A MX2011001046A (es) 2008-07-29 2009-07-29 Regimen de administracion para nitrocatecoles.

Country Status (17)

Country Link
US (1) US20110301204A1 (es)
EP (1) EP2307020B1 (es)
JP (2) JP6165412B2 (es)
KR (3) KR20190079705A (es)
CN (1) CN102355900A (es)
AR (1) AR072846A1 (es)
AU (1) AU2009277196B2 (es)
BR (1) BRPI0913913A2 (es)
CA (1) CA2729288C (es)
DK (1) DK2307020T3 (es)
ES (1) ES2723729T3 (es)
IL (1) IL210393A0 (es)
MX (2) MX2011001046A (es)
PT (1) PT2307020T (es)
RU (1) RU2557532C2 (es)
TR (1) TR201906117T4 (es)
WO (1) WO2010014025A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1907382T3 (pl) 2005-07-26 2016-01-29 Bial Portela & Ca Sa Pochodne nitrokatecholowe jako inhibitory COMT
EP1845097A1 (en) 2006-04-10 2007-10-17 Portela & Ca., S.A. Oxadiazole derivatives as COMT inhibitors
CA2678391C (en) 2007-01-31 2017-01-17 David Alexander Learmonth Dosage regimen for comt inhibitors
RU2010139315A (ru) 2008-03-17 2012-04-27 Биал - Портела Энд Ка., С.А. (Pt) Кристаллические формы 5-[3-(2,5-дихлор-4,6-диметил-1-окси-пиридин-3-ил)[1,2,4]оксадиазол-5-ил]-3-нитробензол-1,2-диола
RU2701731C2 (ru) * 2009-04-01 2019-10-01 Биал-Портела Энд Ка, С.А. Фармацевтические препараты, содержащие производные нитрокатехина, и способы их получения
US8598235B2 (en) 2009-12-04 2013-12-03 Jon E. Grant Treating impulse control disorders with catechol-O-methyl-transferase inhibitors
US20140045900A1 (en) * 2011-02-11 2014-02-13 Bial-Portela & Ca, S.A. Administration regime for nitrocatechols
EP3604299B1 (en) 2011-12-13 2023-07-26 Bial-Portela & CA, S.A. Chemical compound useful as intermediate for preparing a catechol-0-methyl transferase inhibitor
JP2018500300A (ja) 2014-11-28 2018-01-11 ノヴィファーマ，エス．アー． パーキンソン病を遅延させるための医薬
WO2020072886A1 (en) 2018-10-05 2020-04-09 Neurocrine Biosciences, Inc. Methods for the administration of comt inhibitors
CN119775271A (zh) * 2024-12-31 2025-04-08 南京海纳医药科技股份有限公司 一种奥吡卡朋粗品的精制方法
CN120081837A (zh) * 2025-02-14 2025-06-03 江苏天士力帝益药业有限公司 一种低单杂高纯度的奥匹卡朋中间体05的制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10338174A1 (de) * 2003-08-20 2005-03-24 Lts Lohmann Therapie-Systeme Ag Transdermale Arzneimittelzubereitungen mit Wirkstoffkombinationen zur Behandlung der Parkinson-Krankheit
JP2008519811A (ja) * 2004-11-10 2008-06-12 オリオン コーポレーション 下肢静止不能症候群の治療
PL1907382T3 (pl) * 2005-07-26 2016-01-29 Bial Portela & Ca Sa Pochodne nitrokatecholowe jako inhibitory COMT
EP1845097A1 (en) * 2006-04-10 2007-10-17 Portela & Ca., S.A. Oxadiazole derivatives as COMT inhibitors
CA2678391C (en) * 2007-01-31 2017-01-17 David Alexander Learmonth Dosage regimen for comt inhibitors
RU2010139315A (ru) * 2008-03-17 2012-04-27 Биал - Портела Энд Ка., С.А. (Pt) Кристаллические формы 5-[3-(2,5-дихлор-4,6-диметил-1-окси-пиридин-3-ил)[1,2,4]оксадиазол-5-ил]-3-нитробензол-1,2-диола

Also Published As

Publication number Publication date
KR20190079705A (ko) 2019-07-05
TR201906117T4 (tr) 2019-05-21
CA2729288C (en) 2017-01-17
RU2010154173A (ru) 2012-09-10
EP2307020A1 (en) 2011-04-13
KR20180095135A (ko) 2018-08-24
KR20110044949A (ko) 2011-05-03
AR072846A1 (es) 2010-09-22
CA2729288A1 (en) 2010-02-04
IL210393A0 (en) 2011-03-31
ES2723729T3 (es) 2019-08-30
AU2009277196B2 (en) 2015-06-18
AU2009277196A1 (en) 2010-02-04
PT2307020T (pt) 2019-05-28
US20110301204A1 (en) 2011-12-08
JP2011529489A (ja) 2011-12-08
JP2015129163A (ja) 2015-07-16
DK2307020T3 (da) 2019-05-13
WO2010014025A1 (en) 2010-02-04
BRPI0913913A2 (pt) 2015-10-13
EP2307020B1 (en) 2019-02-20
CN102355900A (zh) 2012-02-15
MX2011001046A (es) 2011-03-29
JP6518080B2 (ja) 2019-05-22
RU2557532C2 (ru) 2015-07-20
JP6165412B2 (ja) 2017-07-19

Similar Documents

Publication Publication Date Title
MX360330B (es) Regimen de administracion para nitrocatecoles.
EA201390381A1 (ru) Триазиноксадиазолы
GEP20146146B (en) Pyrrolopyrimidine compounds as inhibitors of cdk4/6
EA201290183A1 (ru) Бензодиазепиновый ингибитор бромодомена
PH12014501514A1 (en) New azetidine derivatives, pharmaceutical compositions and uses thereof
TN2014000016A1 (en) 4 - piperidinyl compounds for use as tankyrase inhibitors
MY173448A (en) Phenyl and benzodioxinly substituted indazoles derivatives
IN2014MN02598A (es)
IN2014CN04530A (es)
GEP20146125B (en) Aminopyrimidines as syk inhibitors
EA201190235A1 (ru) Замещенные 1-цианоэтилгетероциклилкарбоксамидные соединения 750
MY160490A (en) Arylethynyl derivatives
IN2015DN01119A (es)
MX2012013274A (es) Novedosos derivados de la pirimidina.
IN2012DN03182A (es)
IN2012DN02139A (es)
MX348451B (es) Derivados de n-[(1h-pirazol-1-il)aril]-1h-indol o 1h-indazol-3-carboxamida, su preparación y su uso como antagonistas p2y12.
MY186599A (en) Substituted pyridopyrazines as novel syk inhibitors
EA201291217A1 (ru) ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ ПРОИЗВОДНЫЕ 1-(β-D-ГЛЮКОПИРАНОЗИЛ)-2-ТИЕНИЛМЕТИЛБЕНЗОЛА КАК ИНГИБИТОРЫ НЗПГ
PH12013502204A1 (en) 3-spirocyclic piperidine derivatives as ghrelin receptor agonists
UA107455C2 (uk) Похідні індолу як протиракові агенти
PH12015501175A1 (en) Substituted pyridopyrazines as syk inhibitors
TN2011000355A1 (en) Novel microbiocides
MX342960B (es) Derivados de cromeno.
MX2013006670A (es) Derivado de 2-carboxamida-4-piperazinil-benzofurano.